Protocol

HOD08: Reduced Duration Stanford V Chemotherapy With or Without Low-Dose Tailored-Field Radiation Therapy for Favorable Risk Pediatric Hodgkin Lymphoma

Diseases

Leukemias / Lymphomas : Hodgkin lymphoma

Description

This is a research study for participants that have a type of cancer called Hodgkin Lymphoma (cancer of the lymph system). Hodgkin lymphoma is one of the most treatable and curable childhood cancers. The standard treatment involves chemotherapy and radiation therapy. Although most patients get cured from their cancer, some experience bad side effects from treatment later in life, often referred to as “late effects”. It is thought that if some patients can be successfully treated with less intense therapy, these patients might have less “late effects”.

In this study, participants whose disease completely goes away after treatment with 8 weeks of chemotherapy will be finished with treatment. They will not receive radiation therapy. The anti-cancer drug combination that they receive is a reduced duration (8 weeks instead of 12) of Stanford V which is a multi-agent dose-intense chemotherapy with low cumulative doses of the individual chemotherapy agents. Participants whose disease doesn’t go away after the initial treatment with 8 weeks of chemotherapy will receive radiation therapy to the cancer sites.

Objectives

• To increase the complete response rate after 8 weeks Stanford V by at least 20% compared to patients on HOD 99 after 8 weeks VAMP.
• To estimate the disease failure rate within the radiation fields.
• To examine patterns of treatment failure for children treated with low dose tailored field radiation therapy.
• To describe acute hematologic and infectious toxicities as they relate to transfusion requirements, growth factor support, episodes of febrile neutropenia and hospitalizations,
• according to the NCI Common Terminology Criteria for Adverse Events (CTCAE), version 3.0.
• To compare the survival distributions (event free, overall and local failure) and toxicities of favorable risk patients treated with 8 weeks of Stanford V chemotherapy and low-dose tailored-field radiation to those on the favorable risk group of the HOD99.

Eligibility

• Histologically confirmed, previously untreated Hodgkin lymphoma.
• Age: Participants must be 21 years of age or younger
• Must not have intermediate or high risk disease, defined as stage IB, IIIA, any IV or IA/IIA with “E” lesions, 3 or more nodal sites involved, or bulky mediastinal adenopathy

For the current eligibility status of this clinical study, referring physicians must contact St. Jude Children's Research Hospital at 1-866-2ST-JUDE (1-866-278-5833).

Contact Information

Dr. Monika Metzger, MD
St. Jude Children’s Research Hospital
262 Danny Thomas Place
Memphis, TN 38105 USA
Voice: 1-866-2ST-JUDE  (1-866-278-5833)
FAX: 901-595-5068

Referring or consulting physicians only: protocolinfo@stjude.org

For all other inquiries about St. Jude Children's Research Hospital studies: info@stjude.org

 

The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.